Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials.

Jódar E, Romera I, Wang Q, Roche SL, García-Pérez LE

Diabetes, obesity & metabolism19 Dec 2021Cited by 5 (Europe PMC)

PMID34866291PMCIDPMC9300025DOI10.1111/dom.14615PepBankPUB-34866291

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with diabetes without concomitant insulin, dulaglutide reduced within-day self-monitored plasma glucose variability from baseline.
In plain wordsIn patients with diabetes without insulin, daily glucose variation fell from baseline with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWithin-day SMPG variability without insulin
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · Up to 28 weeksAs given in this study (human).
Source sentences
Summary
Pooled data from five studies with dulaglutide as monotherapy or added to oral glucose-lowering medication, without concomitant insulin treatment, revealed clinically meaningful reductions in within- and between-day SMPG, and between-day FSMPG variability from baseline in the dulaglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analyses of six randomized, phase 3 studies were conducted to investigate the association between treatment with dulaglutide 1.5 mg once weekly and GV in adult patients with T2D.
Summary · context
Using data from seven- and eight-point self-monitored plasma glucose (SMPG) profiles over up to 28 weeks of treatment, GV in within- and between-day SMPG, and between-day fasting glucose from SMPG (FSMPG) was assessed according to standard deviation and coefficient of variation.
Report a problemFND-3486629101
02HumanRandomized controlled trialEfficacy outcome
In patients with diabetes without concomitant insulin, dulaglutide reduced between-day self-monitored plasma glucose variability from baseline.
In plain wordsIn patients with diabetes without insulin, glucose variation between days fell from baseline with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBetween-day SMPG variability without insulin
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · Up to 28 weeksAs given in this study (human).
Source sentences
Summary
Pooled data from five studies with dulaglutide as monotherapy or added to oral glucose-lowering medication, without concomitant insulin treatment, revealed clinically meaningful reductions in within- and between-day SMPG, and between-day FSMPG variability from baseline in the dulaglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analyses of six randomized, phase 3 studies were conducted to investigate the association between treatment with dulaglutide 1.5 mg once weekly and GV in adult patients with T2D.
Summary · context
Using data from seven- and eight-point self-monitored plasma glucose (SMPG) profiles over up to 28 weeks of treatment, GV in within- and between-day SMPG, and between-day fasting glucose from SMPG (FSMPG) was assessed according to standard deviation and coefficient of variation.
Report a problemFND-3486629102
03HumanRandomized controlled trialEfficacy outcome
In patients with diabetes without concomitant insulin, dulaglutide reduced between-day fasting glucose variability from baseline.
In plain wordsIn patients with diabetes without insulin, fasting glucose variation between days fell from baseline with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBetween-day fasting glucose variability without insulin
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · Up to 28 weeksAs given in this study (human).
Source sentences
Summary
Pooled data from five studies with dulaglutide as monotherapy or added to oral glucose-lowering medication, without concomitant insulin treatment, revealed clinically meaningful reductions in within- and between-day SMPG, and between-day FSMPG variability from baseline in the dulaglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analyses of six randomized, phase 3 studies were conducted to investigate the association between treatment with dulaglutide 1.5 mg once weekly and GV in adult patients with T2D.
Summary · context
Using data from seven- and eight-point self-monitored plasma glucose (SMPG) profiles over up to 28 weeks of treatment, GV in within- and between-day SMPG, and between-day fasting glucose from SMPG (FSMPG) was assessed according to standard deviation and coefficient of variation.
Report a problemFND-3486629103
04HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide reduced within-day self-monitored plasma glucose variability more than insulin glargine.
In plain wordsIn patients with diabetes, dulaglutide reduced daily glucose variation more than insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWithin-day SMPG variability versus glargine
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · Up to 28 weeksAs given in this study (human).
Source sentences
Summary
Comparisons between treatment groups in two studies demonstrated that reductions from baseline in within-day and between-day SMPG, and between-day FSMPG variability were greater for treatment with dulaglutide compared with insulin glargine,
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analyses of six randomized, phase 3 studies were conducted to investigate the association between treatment with dulaglutide 1.5 mg once weekly and GV in adult patients with T2D.
Summary · context
Using data from seven- and eight-point self-monitored plasma glucose (SMPG) profiles over up to 28 weeks of treatment, GV in within- and between-day SMPG, and between-day fasting glucose from SMPG (FSMPG) was assessed according to standard deviation and coefficient of variation.
Report a problemFND-3486629104
05HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide reduced between-day self-monitored plasma glucose variability more than insulin glargine.
In plain wordsIn patients with diabetes, dulaglutide reduced glucose variation between days more than insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBetween-day SMPG variability versus glargine
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · Up to 28 weeksAs given in this study (human).
Source sentences
Summary
Comparisons between treatment groups in two studies demonstrated that reductions from baseline in within-day and between-day SMPG, and between-day FSMPG variability were greater for treatment with dulaglutide compared with insulin glargine,
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analyses of six randomized, phase 3 studies were conducted to investigate the association between treatment with dulaglutide 1.5 mg once weekly and GV in adult patients with T2D.
Summary · context
Using data from seven- and eight-point self-monitored plasma glucose (SMPG) profiles over up to 28 weeks of treatment, GV in within- and between-day SMPG, and between-day fasting glucose from SMPG (FSMPG) was assessed according to standard deviation and coefficient of variation.
Report a problemFND-3486629105
06HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide reduced between-day fasting glucose variability more than insulin glargine.
In plain wordsIn patients with diabetes, dulaglutide reduced fasting glucose variation between days more than insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBetween-day fasting glucose variability versus glargine
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · Up to 28 weeksAs given in this study (human).
Source sentences
Summary
Comparisons between treatment groups in two studies demonstrated that reductions from baseline in within-day and between-day SMPG, and between-day FSMPG variability were greater for treatment with dulaglutide compared with insulin glargine,
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analyses of six randomized, phase 3 studies were conducted to investigate the association between treatment with dulaglutide 1.5 mg once weekly and GV in adult patients with T2D.
Summary · context
Using data from seven- and eight-point self-monitored plasma glucose (SMPG) profiles over up to 28 weeks of treatment, GV in within- and between-day SMPG, and between-day fasting glucose from SMPG (FSMPG) was assessed according to standard deviation and coefficient of variation.
Report a problemFND-3486629106
07HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, adding dulaglutide to glargine reduced within-day glucose variability more than glargine alone.
In plain wordsIn patients with diabetes, dulaglutide plus glargine reduced daily glucose variation more than glargine alone.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWithin-day SMPG variability with glargine
Study
n: not reported in source
Comparator
Insulin glargine alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · Up to 28 weeksAs given in this study (human).
Source sentences
Summary
Comparisons between treatment groups in two studies demonstrated that reductions from baseline in within-day and between-day SMPG, and between-day FSMPG variability were greater for treatment with dulaglutide compared with insulin glargine, as well as for treatment with dulaglutide when added to ins…
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analyses of six randomized, phase 3 studies were conducted to investigate the association between treatment with dulaglutide 1.5 mg once weekly and GV in adult patients with T2D.
Summary · context
Using data from seven- and eight-point self-monitored plasma glucose (SMPG) profiles over up to 28 weeks of treatment, GV in within- and between-day SMPG, and between-day fasting glucose from SMPG (FSMPG) was assessed according to standard deviation and coefficient of variation.
Report a problemFND-3486629107
08HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, adding dulaglutide to glargine reduced between-day glucose variability more than glargine alone.
In plain wordsIn patients with diabetes, dulaglutide plus glargine reduced glucose variation between days more than glargine alone.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBetween-day SMPG variability with glargine
Study
n: not reported in source
Comparator
Insulin glargine alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · Up to 28 weeksAs given in this study (human).
Source sentences
Summary
Comparisons between treatment groups in two studies demonstrated that reductions from baseline in within-day and between-day SMPG, and between-day FSMPG variability were greater for treatment with dulaglutide compared with insulin glargine, as well as for treatment with dulaglutide when added to ins…
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analyses of six randomized, phase 3 studies were conducted to investigate the association between treatment with dulaglutide 1.5 mg once weekly and GV in adult patients with T2D.
Summary · context
Using data from seven- and eight-point self-monitored plasma glucose (SMPG) profiles over up to 28 weeks of treatment, GV in within- and between-day SMPG, and between-day fasting glucose from SMPG (FSMPG) was assessed according to standard deviation and coefficient of variation.
Report a problemFND-3486629108
09HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, adding dulaglutide to glargine reduced between-day fasting glucose variability more than glargine alone.
In plain wordsIn patients with diabetes, dulaglutide plus glargine reduced fasting glucose variation between days more than glargine alone.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBetween-day fasting glucose variability with glargine
Study
n: not reported in source
Comparator
Insulin glargine alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · Up to 28 weeksAs given in this study (human).
Source sentences
Summary
Comparisons between treatment groups in two studies demonstrated that reductions from baseline in within-day and between-day SMPG, and between-day FSMPG variability were greater for treatment with dulaglutide compared with insulin glargine, as well as for treatment with dulaglutide when added to ins…
2 context sentences(design, population, supporting numbers)
Summary · context
Post hoc analyses of six randomized, phase 3 studies were conducted to investigate the association between treatment with dulaglutide 1.5 mg once weekly and GV in adult patients with T2D.
Summary · context
Using data from seven- and eight-point self-monitored plasma glucose (SMPG) profiles over up to 28 weeks of treatment, GV in within- and between-day SMPG, and between-day fasting glucose from SMPG (FSMPG) was assessed according to standard deviation and coefficient of variation.
Report a problemFND-3486629109

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials.

Summary

Results from this study9

Version history

Subjects

Publication types

MeSH terms

Keywords